<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02760888</url>
  </required_header>
  <id_info>
    <org_study_id>EDCU HY</org_study_id>
    <nct_id>NCT02760888</nct_id>
  </id_info>
  <brief_title>Oral Tramadol Versus Diclofenac For Pain Relief Before Outpatient Hysteroscopy:</brief_title>
  <acronym>OPH</acronym>
  <official_title>Oral Tramadol Versus Diclofenac For Pain Relief Before Outpatient Hysteroscopy: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is there difference between the effect of Tramadol orally and
      Diclofenac orally with respect to : analgesic efficacy during diagnostic hysteroscopy in
      nulliparous women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective double-blind, randomized, clinical trial, will be conducted at Ain Shams
      University Maternity Hospital- Early Cancer Detection Unite [ECDU].

      Patients fulfilling inclusion and exclusion criteria will be divided into three groups.

      Group A (study group) Include 34 patients who will receive Tramadol 100mg orally 1 hour
      before the procedure.

      Group B (study group) Include 34 patients who will receive Diclofenac 100mg orally 1 hour
      before the procedure.

      Group C (control group) Include 34 patients who will receive a placebo.

      Pain will evaluate on two separate occasion: immediately after the procedure and 15 minutes
      after procedure using a 100mm line visual analog scale.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain during the procedure</measure>
    <time_frame>intraoperative</time_frame>
    <description>Pain will be assessed using a visual analogue scale immediatly after inserting the hysterscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain after the procedure</measure>
    <time_frame>15 minutes after completing the procedure</time_frame>
    <description>15 minutes after procedure using a 100mm line visual analog scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effect and difficulties</measure>
    <time_frame>24 hours</time_frame>
    <description>Recorded in Case Record Form</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Pain, Procedure</condition>
  <arm_group>
    <arm_group_label>Tramadol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will receive oral tramadol 100 mg 1 hour before the procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diclofenac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will receive 100 mg diclofenac 1 hour before the procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Women will receive a placebo 1 hour before the procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol</intervention_name>
    <description>Women will receive a oral Tramadol 100mg 1 hour before the procedure</description>
    <arm_group_label>Tramadol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac</intervention_name>
    <description>Women will receive oral Diclofenac 100mg 1 hour before the procedure</description>
    <arm_group_label>Diclofenac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Women will receive a Placebo 1 hour before the procedure</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI raging between (18.5 - 30 ).

          -  Scheduled for diagnostic hysteroscopy only.

          -  All of them should have given informed written consent.

        Exclusion Criteria:

          -  Any contraindication to hysteroscopy (e.g. suspected pregnancy, genital tract
             infection).

          -  Receiving any other form of analgesia.

          -  Patients with known cervical stenosis, polyps and ulcers.

          -  Previous cervical surgery.

          -  Patients who are planning to have invasive intrauterine therapeutic interventions
             during the hysteroscopy.

          -  known sensitivity to non-steroidal anti-inflammatory and opioids drugs.

          -  Known gastritis or peptic ulcer or cardiac disease or Respiratory dysfunction.

          -  Unwilling to comply with the protocol, and Participation in another clinical trial in
             the last three months prior to the start of this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed Elsayed Elbohoty, MD</last_name>
    <email>elbohoty79@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2016</study_first_posted>
  <last_update_submitted>May 3, 2016</last_update_submitted>
  <last_update_submitted_qc>May 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Ahmed Elsayed Hassan Elbohoty</investigator_full_name>
    <investigator_title>Assistant professor of Obstetrics and Gynecology Faculty of Medicine Ain Shams University</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

